Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 10:30 ET | Source: PatentVest, Inc.

New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market

· Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms. · PatentVest’s report reveals how...
April 28, 2026 07:25 ET | Source: FormBlends

FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States

MIAMI, FL, April 28, 2026 (GLOBE NEWSWIRE) -- FormBlends, a telehealth platform focused on medically supervised GLP-1 therapy and peptide research, today released its 2026 State of Peptides and...
April 23, 2026 07:00 ET | Source: Nasdaq, Inc.

Nasdaq Reports First Quarter 2026 Results; Strong Execution Drives Double-Digit Net Revenue Growth Across All Divisions

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the first quarter of 2026. First quarter 2026 net revenue1 was $1.4 billion, an...
April 22, 2026 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Board Chair Transition

PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of...
April 20, 2026 16:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kailera Therapeutics, Inc. (Nasdaq: KLRA), an advanced clinical-stage biotechnology company, today announced the closing of its initial public offering.
April 16, 2026 19:25 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces Pricing of Initial Public Offering

Kailera Therapeutics, Inc. (Nasdaq: KLRA) today announced the pricing of its initial public offering.
April 15, 2026 07:00 ET | Source: Beeline Medicines Corporation

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential...
March 05, 2026 09:00 ET | Source: Vera Therapeutics

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Vera Therapeutics Appoints Christopher Hite to Board of Directors
February 10, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
January 22, 2026 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...